Concomitant <i>PIK3CA</i> and <i>TP53</i> Mutations in Breast Cancer: An Analysis of Clinicopathologic and Mutational Features, Neoadjuvant Therapeutic Response, and Prognosis.

However, for patients with BC treated with anti-HER2 neoadjuvant therapy ( Figure 3C ), the distinction was slightly below the level of significance ( TP53 mutant vs. co-mutant; OR, 4.000; 95% CI, 0.976–18.487; p = 0.062).

also in 8 other papers